Tropinol Esters Modulate APP Cleavage to Reduce Beta-Amyloid
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Alzheimer's disease primarily focus on reducing beta-amyloid levels without addressing the underlying imbalance in physiological signaling processes, leading to limited cognitive improvement and potential side effects.
Innovation Solution
The use of tropinol esters and related compounds to modulate amyloidogenic pathologies by promoting the non-amyloidogenic processing of the amyloid precursor protein (APP), inhibiting C-terminal cleavage, and reducing beta-amyloid deposits in the brain, thereby mitigating symptoms and delaying disease progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If beta-amyloid levels are reduced through current treatments, then amyloid deposits decrease, but cognitive improvement is limited and side effects occur
Solution Approach 1:
The patent extracts and eliminates the harmful C-terminal cleavage pathway of APP that produces neurotoxic fragments (APPneo and Aβ31). By using compounds that selectively inhibit this specific pathological pathway while preserving normal APP processing, the treatment removes the toxic component without disrupting beneficial physiological functions, thereby achieving better cognitive outcomes with fewer side effects
Solution Approach 2:
The patent changes the processing parameter of APP by shifting the cleavage site from the C-terminal region to alternative pathways. This parameter change in protein processing prevents the formation of toxic fragments while maintaining or enhancing beneficial APP metabolites, leading to improved cognitive function without the limitations of current beta-amyloid reduction approaches
2Object-generated harmful factors
If C-terminal cleavage of APP is inhibited, then neurotoxic peptide formation decreases, but disease progression may be affected
Solution Approach 1:
Instead of focusing on reducing beta-amyloid levels as current treatments do, the patent inverts the approach by targeting the upstream C-terminal cleavage event that generates neurotoxic fragments. By blocking this upstream pathological step, the treatment prevents the formation of multiple toxic species simultaneously, offering a more comprehensive and durable disease modification effect
Solution Approach 2:
The patent applies preliminary action by inhibiting the C-terminal cleavage of APP before neurotoxic peptides can form and cause damage. This upstream intervention prevents the generation of toxic fragments in the first place, providing long-lasting protection against disease progression rather than merely clearing existing amyloid deposits
Data Source
AI summary
In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.